Randi Leavitt Selected Research

terminase

1/2022	Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.
1/2020	Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Randi Leavitt Research Topics

Disease

5	Infections 01/2022 - 09/2009
1	Cytomegalovirus Infections (Inclusion Disease) 01/2020
1	HIV Infections (HIV Infection) 01/2020
1	Coinfection 11/2017
1	Dizziness (Lightheadedness) 11/2017
1	Headache (Headaches) 11/2017
1	Hepatitis B 11/2017
1	Nausea 11/2017
1	Hyperbilirubinemia 05/2012

Drug/Important Bio-Agent (IBA)

3	letermovirIBA 01/2022 - 01/2020
2	terminaseIBA 01/2022 - 01/2020
2	Raltegravir Potassium FDA Link 11/2017 - 09/2009
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Valganciclovir FDA Link 01/2020
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Emtricitabine (Emtriva)FDA Link 11/2017
1	Tenofovir (Viread)FDA Link 11/2017
1	Pharmaceutical PreparationsIBA 11/2017
1	RNA (Ribonucleic Acid)IBA 11/2017
1	RacivirIBA 05/2012
1	efavirenz (Sustiva)FDA Link 09/2009

Therapy/Procedure

2	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2020
2	Therapeutics 01/2020 - 09/2009
1	Transplantation 01/2022